Why the study?
Distinguishing severe multifactorial hypertriglyceridemia from the monogenetic form remains challenging because decompensated multifactorial cases can clinically mimic monogenetic severity.
Does the FCS score accurately distinguish familial chylomicronemia syndrome from multifactorial causes in patients with severe hypertriglyceridemia?
Does the FCS score accurately distinguish familial chylomicronemia syndrome from multifactorial causes in patients with severe hypertriglyceridemia?
The FCS score is a valid clinical tool with high specificity for distinguishing monogenic familial chylomicronemia syndrome from multifactorial causes in patients with severe hypertriglyceridemia.
Answers are grounded in this paper and cite their sources.
May support FCS differentiation in severe hypertriglyceridemia; leaves open prospective validation before clinical adoption.
BACKGROUND: Severe hypertriglyceridemia (HTG) has predominantly multifactorial causes (MCS). Yet a small subset of patients have the monogenetic form (FCS). It remains a challenge to distinguish patients clinically, since decompensated MCS might mimic FCS´s severity. Aim of the current study was to determine clinical criteria that could sufficiently distinguish both forms as well as to apply the FCS score proposed by Moulin and colleagues. METHODS: We retrospectively studied 72 patients who presented with severe HTG in our clinic during a time span of seven years and received genetic testing. We classified genetic variants (ACMG-criteria), followed by genetic categorization into MCS or FCS. Clinical data were gathered from the medical records and the FCS score was calculated for each patient. RESULTS: Molecular genetic screening revealed eight FCS patients and 64 MCS patients. Altogether, we found 13 pathogenic variants of which four have not been described before. The FCS patients showed a significantly higher median triglyceride level compared to the MCS. The FCS score yielded a sensitivity of 75% and a specificity of 93.7% in our cohort, and significantly differentiated between the FCS and MCS group (p<0.001). CONCLUSIONS: In our cohort we identified several variables that significantly differentiated FCS from MCS. The FCS score performed similar to the original study by Moulin, thereby further validating the discriminatory power of the FCS score in an independent cohort.
No takes yet. Share an insight, caveat, or question.
Bardey et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: